Barclays maintained a Sell rating on Puma Biotechnology (PBYI), noting that Trump-era tariffs and onshoring trends benefit AI stocks.

The entities involved

• Donald Trump →

  American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)

  • Trump ended the ceasefire agreement with Iran following recent attacks by Iranian forces.Mon 18:02
  • The Trump administration utilized the Department of Health & Human Services for an AI tool.Mon 18:02
• Barclays →

  British bank

  • QinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.Mon 13:19
  • Financial institutions provided ratings on multiple companies on July 8, 2026, including Goldman Sachs reiterating Tesla as neutral, Barclays initiating Toast as overweight, and Bank of America rating Nvidia as a buy.Sun 14:53
• Puma Biotechnology (United States) →

  company in Los Angeles, United States

  Nothing else this week.

Related events

• Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.Jun 7
• AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.Jun 8
• Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.Jun 7
• SharpLink Gaming acquired Ethereum above market prices, causing a stock price drop, while Trump tariffs continue to benefit AI stocks.Jun 7
• AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.Jun 7